CoChat

Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer

Open access
Huemer, Florian, Rinnerthaler, Gabriel, Westphal, Theresa, Hackl, Hubert, Hutarew, Georg, Gampenrieder, Simon Peter, Weiss, Lukas, Greil, Richard · 2018 · Oncotarget
Cited by 87

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

// Florian Huemer 1, * , Gabriel Rinnerthaler 1, * , Theresa Westphal 1 , Hubert Hackl 4 , Georg Hutarew 5 , Simon Peter Gampenrieder 1 , Lukas Weiss 1 and Richard Greil 1, 2, 3 1 IIIrd Medical Department, Paracelsus Medical University Salzburg, Salzburg, Austria 2 Salzburg Cancer Research Institute (SCRI), Salzburg, Austria 3 Cancer Cluster Salzburg (CCS), Salzburg, Austria 4 Division of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, Austria 5 Institute of Pathology, Paracelsus Medical University Salzburg, Salzburg, Austria * These authors have contributed equally to this work Correspondence to: Richard Greil, email: r.greil@salk.at Keywords: immune-checkpoint blockade; antibiotics; non-squamous non-small cell lung cancer; progression-free survival; overall survival Received: October 19, 2017 Accepted: March 05, 2018 Published: March 27, 2018 ABSTRACT Introduction: Despite durable responses from immune-checkpoint blockade (ICB) in a subset of patients with advanced non-small cell lung cancer (NSCLC), the majority of patients do not derive benefit from this treatment. In this analysis we evaluated the impact of concomitant administration of antibiotics during initiation of ICB on clinical outcome. Methods: Advanced non-squamous NSCLC patients receiving ICB as second- or later line between 2015 and 2017 at our tertiary cancer center in Salzburg (Austria) were included. Concomitant use of antibiotics was defined as administration of antibiotics within a time frame of one month before or one month after initiation of ICB (AB + -group). Results: Of the 30 patients included, 11 (36.7%) received antibiotics one month before or one month after start of ICB (AB + -group). Median PFS on ICB was in favor of the AB - -group (AB - : 3.1 months [95%CI: 3.0-16.3]; AB + : 2.9 months, [95%CI: 1.9-NA]; HR=0.46 [95%CI: 0.12-0.90], p=0.031). Furthermore, median OS was significantly longer in the AB - -group (AB - : 15.1 months [95%CI: 11.1-NA]; AB + : 7.5 months [95%CI: 6.3-NA]; HR=0.31 [95%CI: 0.02-0.78], p=0.026). In a multivariate analysis, the antibiotic treatment status was identified as the only parameter statistically significantly associated with PFS (p=0.028) and OS (p=0.026). Conclusions: Stratification of patients according to the antibiotic treatment status is warranted in future trials investigating ICB.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.24751

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

Metadata

Authors
Huemer, F., Rinnerthaler, G., Westphal, T., Hackl, H., Hutarew, G., Gampenrieder, S. P., Weiss, L., & Greil, R.
Venue
Oncotarget
Published
2018-03-27
Volume
9
Issue
23
Pages
16512-16520
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2795291772
Cited by
87
References
5
FWCI
4.47
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.